Clinical Trial Update: Ventilator Adapters for Combivent Respimat [Phase 4]

View source ↗

Summary

A Phase 4 study evaluating ventilator adapters for Boehringer Ingelheim's Combivent Respimat was terminated, with results posted on 2016-02-15.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Combivent Respimat (ipratropium bromide and albuterol sulfate)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 4 | Status: TERMINATED | Results posted: 2016-02-15